Galmed Pharmaceuticals Has Been Granted European Patent Number EP3538158 Titled "Treatment For Fibrosis (Including Methods For Inhibition Of Fibrotic Disorders And Hepato-Fibrotic Conditions Associated With NAFLD And NASH)"
Portfolio Pulse from Benzinga Newsdesk
Galmed Pharmaceuticals has been granted European Patent Number EP3538158 for the treatment of fibrosis, including methods for inhibition of fibrotic disorders and hepato-fibrotic conditions associated with NAFLD and NASH.
October 02, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The granting of the European patent to Galmed Pharmaceuticals could potentially increase the company's market share and revenues in the European market.
The granting of a patent provides Galmed Pharmaceuticals with exclusive rights to the patented treatment methods in Europe. This could potentially lead to increased sales and revenues for the company in the European market. Furthermore, it could also enhance the company's competitive position in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100